Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

BACKGROUND: The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monot...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Commun (Lond)
Main Authors: Huang, Jing, Xu, Binghe, Liu, Ying, Huang, Junxing, Lu, Ping, Ba, Yi, Wu, Lin, Bai, Yuxian, Zhang, Shu, Feng, Jifeng, Cheng, Ying, Li, Jie, Wen, Lu, Yuan, Xianglin, Ma, Changwu, Hu, Chunhong, Fan, Qingxia, Wang, Xi
格式: Artigo
語言:Inglês
出版: BioMed Central 2019
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444575/
https://ncbi.nlm.nih.gov/pubmed/30940189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0359-7
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍